Openbookopenbook
Equity
WuXi AppTec Co. Ltd(WUXIF)
USD --+0.00%
Reward69High
Risk15Low
📊75%Data
Strong 34% profit margin · 9.6% dividend yield · Revenue growing 10% YoY
WUXIF
+0.0 · +0.00%
USD · PINK
WuXi AppTec Co. Ltd | Healthcare
Dividend King
Market Cap:41.41Bn
ℹ️
Reward Rating
69
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
15
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on WUXIF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is WuXi AppTec Co. Ltd?

, an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally.

WUXIF · Verdict

Solid reward · low risk

WUXIF scores well on balance sheet and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

WUXIF · Verdict

What’s working & what to watch

Strengths 5

  • Balance sheet96/100

    Interest covered 54.4×

  • Cash flow91/100

    21% free-cash-flow margin

  • Growth82/100

    Rev +19.7% CAGR · earnings +22.8%

  • Profitability71/100

    24% net margin · 26% ROE

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is WuXi AppTec Co. Ltd?

, an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 41.41B, and a P/E ratio of 18.3x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (69)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap41.41B
P/E Ratio18.2632
Dividend Yield9.60%
52 Week High16.8
52 Week Low6.9567
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding510M
No. of Employees39,414
IndustryDiagnostics & Research
ExchangePINK
Beta0.623
CurrencyUSD
Websitewww.wuxiapptec.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.